01—Abstract
Summary
Summary of the 8-K filed June 29, 2026. Cited figures are marked; the original filing is the authoritative source.
Corteva, Inc. (NYSE: CTVA) filed an 8-K on June 29, 2026 disclosing board changes tied to its planned separation of its seed business into a new, independent public company, Vylor, Inc. Four current directors (Karen Grimes, Marcos Lutz, Charles Magro, and Kerry Preete) agreed with the Board to resign effective immediately before the spin-off is consummated.
The departures are described as unrelated to any disagreement with the company's operations, policies, or practices. Each is expected to join the Vylor board, which signals that the separation is progressing and that leadership is being staffed for both companies. The filing also announced the post-separation boards.
Corteva's nine-person board will be chaired by Greg Page, former chairman and CEO of Cargill, and will include Luke Kissam, named future CEO of Corteva, effective at separation. The company positions the remaining Corteva as a pure-play, asset-light crop protection business focused on innovation and operational efficiency. Vylor's seven-person board will be chaired by Karen Grimes and includes Chuck Magro as future CEO.
Vylor is described as an advanced seed and genetics company that will expand its licensing business and explore new row crops. The company said at least one additional Vylor board seat remains open. Vylor also made its first public Form 10 registration filing with the SEC, which contains detailed information on its business, strategy, and historical financials.
Management reaffirmed that the separation remains on track for the fourth quarter of 2026. Investors should note that the announcement is largely governance and transition-focused, with no new financial results, guidance, or transaction terms disclosed in this 8-K. The Form 10 is the primary source for Vylor's financial profile, and the spin-off still carries execution, timing, and separation-cost risks as described in the forward-looking statements.
02—Key points
Key Highlights
- Four directors (Grimes, Lutz, Magro, Preete) will resign from Corteva's board effective immediately before the spin-off, and all four are slated to join Vylor's board; the company states the resignations are not due to any disagreement.
- Corteva's post-separation board will have nine members, chaired by Greg Page, with Luke Kissam joining at separation as future CEO of Corteva.
- Vylor's post-separation board will have seven members, chaired by Karen Grimes, with Chuck Magro as future CEO; at least one additional board seat remains under search.
- Corteva will be repositioned as an innovation-driven, asset-light crop protection company with targeted growth investments.
- Vylor will focus on advanced seed and genetics, including gene editing and molecular breeding, and expand its licensing business and row-crop opportunities.
- Vylor filed its first public Form 10 registration statement with the SEC, providing detailed business, strategy, and historical financial information.
- The separation remains on track for the fourth quarter of 2026, though the filing includes no new financial results, guidance, or transaction terms.
03—Questions
Frequently Asked Questions
Why are four Corteva directors leaving the board?
Karen Grimes, Marcos Lutz, Charles Magro, and Kerry Preete are resigning from Corteva's board effective immediately before the spin-off of the seed business. Each is expected to join the board of Vylor, the new independent company. The company says the resignations are not the result of any disagreement over operations, policies, or practices.
Who will lead Corteva and Vylor after the separation?
Greg Page, former chairman and CEO of Cargill, will chair Corteva's board, and Luke Kissam will become Corteva's CEO at separation. Karen Grimes will chair Vylor's board, and Chuck Magro will serve as Vylor's CEO.
What is the timing of the spin-off?
Management said the separation remains on track for the fourth quarter of 2026. The board changes take effect at separation, so the timing depends on completing the transaction as planned.
What does Vylor's business look like?
According to the press release, Vylor will be an advanced seed and genetics company built on elite germplasm and biotechnology, including gene editing and molecular breeding. It plans to strengthen its core business, explore new row crops, and significantly expand its licensing business. The Form 10 registration statement contains more detailed information on its strategy and historical financials.
Does this filing include financial results or guidance?
No. The 8-K covers board appointments, the Form 10 filing, and related press releases. It does not include new financial results, guidance, or separation terms. Investors should review Vylor's Form 10 and Corteva's future filings for financial details, and note the risks listed in the forward-looking statements.
04—Continue